|
| Press Releases |
|
 |
|
| Tuesday, April 26, 2022 |
|
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
| Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
| Sunday, April 24, 2022 |
|
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
| 君联资本联合创建企业朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣布，公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性（IRD）患者的临床试验申请，已获得中国国家药品监督管理局药品审评中心（CDE）批准。 more info >> |
|
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
| 君聯資本聯合創建企業朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣佈，公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性（IRD）患者的臨床試驗申請，已獲得中國國家藥品監督管理局藥品審評中心（CDE）批准。 more info >> |
|
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
| Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
| Thursday, April 7, 2022 |
|
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
| 3月31日，君联资本所投创新型疫苗领军企业瑞科生物（股票代码：02179.HK）在港交所成功上市。此次在港上市，成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日，君聯資本所投創新型疫苗領軍企業瑞科生物（股票代碼：02179.HK）在港交所成功上市。此次在港上市，成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。
more info >> |
|
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
| On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, March 8, 2022 |
|
|
从边缘走向舞台中央：君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
| 据联想控股微空间报导，「专精特新」的灵魂是创新，强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性，加强基础研究，推动应用研究，开展补链强链专项行动，加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中，也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
|
從邊緣走向舞台中央：君聯資本所投生物技術產業鏈上游專精特新企業的奮鬥之路 |
| 據聯想控股微空間報導，「專精特新」的靈魂是創新，強調「專精特新」就是要鼓勵創新。政策目標在於強化科技創新和產業鏈供應鏈韌性，加強基礎研究，推動應用研究，開展補鏈強鏈專項行動，加快解決「卡脖子」難題。聯想控股旗下君聯資本不僅有幸參與到眾多「專精特新」企業的發展中，也踐行著將「前瞻性」及「硬科技」作為關鍵字的投資理念。 more info >> |
|
| Thursday, March 3, 2022 |
|
|
Inceptio Technology Completes Financing of US$188 Million, Jointly Led by Legend Capital |
| On 28 February 2022, Inceptio Technology, an autonomous driving truck technology and operation company, announced its completion of a US$188 million Series B+ equity financing, jointly led by Legend Capital. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
可持续发展三大支柱引领 海通恒信ESG必答卷高分亮相
Apr 26, 2024 15:28 HKT/SGT
|
|
|
可持續發展三大支柱引領 海通恆信ESG必答卷高分亮相
Apr 26, 2024 15:25 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 14:34: JST
|
|
|
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について
Apr 26, 2024 14:00: JST
|
|
|
中滙集團公佈2024財年中期業績
Apr 26, 2024 13:51 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Interim Results
Apr 26, 2024 13:43 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 13:27 HKT/SGT
|
|
|
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting
Apr 26, 2024 13:16 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 11:00 HKT/SGT
|
|
|
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
|
|
|
Jeff Martin Auctioneers to Manage Sale of Sabine Mining Company Assets for North American Coal
Apr 26, 2024 08:00 HKT/SGT
|
|
|
Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase
Apr 25, 2024 21:00 HKT/SGT
|
|
|
黑桃资本向香港红十字会捐赠艺术珠宝收藏品
Apr 25, 2024 20:53 HKT/SGT
|
|
|
黑桃資本向香港紅十字會捐贈藝術珠寶收藏品
Apr 25, 2024 20:48 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
